New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For KEG;A;VVC;ELLI;LOGM;CBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
09:14 EDTLOGMJefferies software analysts hold an analyst/industry conference call
Subscribe for More Information
07:26 EDTKEGUBS to hold a conference
Subscribe for More Information
May 19, 2015
09:20 EDTKEGCitadel Advisors reports 5.2% passive stake in Key Energy
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
17:33 EDTLOGMPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
10:23 EDTELLIEllie Mae management to meet with Oppenheimer
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
10:00 EDTKEGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:46 EDTKEGKey Energy upgraded to Equal Weight from Underweight at Stephens
Subscribe for More Information
07:27 EDTKEGKey Energy upgraded to Equal Weight from Underweight at Stephens
Subscribe for More Information
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
09:14 EDTCBSApps World to hold a conference
Subscribe for More Information
08:31 EDTCBSApple likely to launch TV video service this year, says Pacific Crest
Subscribe for More Information
07:06 EDTCBSCBS management to meet with UBS
Subscribe for More Information
06:41 EDTCBSTV networks touting digital, targeting technologies to marketers, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use